Denis Moro-Sibilot
Denis Moro-Sibilot is an expert in Oncology at Centre Hospitalier Universitaire de Grenoble (France). As of September 2026, ScienceLeadR ranks Denis Moro-Sibilot in the top 1% of experts worldwide for Bronchial Neoplasms, Thoracic Neoplasms and Lung Neoplasms. Denis Moro-Sibilot has authored 554 publications, the most recent in 2026, and is an investigator in 77 clinical trials, 22 of them ongoing. SLR score: 2,446 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Immunology - Pulmonology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2026
Number : 554
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. PMID 42212913 — progression-free survival, neoplasms, disease progression, carcinoma, non-small-cell lung, drug therapy, drug-related side effects and adverse reactions, exons, therapeutics, mutation, chemotherapy | N Engl J Med Top journal | 2026 | 0 |
| PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients. PMID 41859082 — injections, immunity, humoral, cells, antibody formation, vaccines, antibodies, translational research, biomedical, neoplasms, immunotherapy, vaccination, immune system diseases, immunity, transplants, therapeutics, dendritic cells, cancer vaccines | Front Immunol | 2026 | 0 |
| Innovative therapeutic cancer vaccine PDC ∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer. PMID 41101155 — cells, lung, safety, vaccines, neoplasms, carcinoma, non-small-cell lung, immune checkpoint inhibitors, lung neoplasms, small cell lung carcinoma, immunity, therapeutics, cancer vaccines | ESMO Open | 2025 | 0 |
| Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study. PMID 40946253 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, lung neoplasms, small cell lung carcinoma, nivolumab, therapeutics, chemotherapy | Oncol Ther | 2025 | 0 |
| MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial. PMID 40914144 — pemetrexed, mesothelioma, micrornas, bevacizumab, predictive value of tests, drug therapy, biomarkers, therapeutics, chemotherapy | Transl Oncol | 2025 | 5 |
Clinical Studies 77
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
22 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Test How Well ZL 1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer 2025-522818-23-00 — cells, lung, pharmaceutical preparations, neoplasms, lung neoplasms, small cell lung carcinoma, work, therapeutics | Phase 3 | Not yet recruiting | 2026 |
| A multicentre Phase II single arm interventional study of neoadjuvant durvalumab and platinum based chemotherapy (CT) followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab in participants with resectable or borderline resectable stage IIB IIIB Nonsmall Cell Lung Cancer (NSCLC) 2023-503357-35-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, chemotherapy | Phase 2 | Active not recruiting | 2024 |
| A Randomized Double Blind Placebo Controlled MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004 TAB004) as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy 2023-507097-41-01 — cells, lung, neoplasms, disease progression, multiple chronic conditions, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, therapeutics | Phase 3 | Active not recruiting | 2025 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First line Treatment of PD L1 high Metastatic Non small Cell Lung Cancer 2024-517780-24-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics | Phase 3 | Recruiting | 2025 |
| A Study to Learn About the Study Medicine Called PF 08046054 SGNPDL1V Versus Docetaxel in Adult Participants with Previously treated Programmed Cell Death Ligand 1 (PD L1) Positive Non small cell Lung Cancer (NSCLC) 2025-521281-97-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, ligands, cell death | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map